BCYC · Bicycle Therapeutics PLC
$3.87
-0.08 (-1.90%)
At close · Jul 29
Market Cap
$275.06M
Shares
69.81M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$72.59M
+105.8%
FY2025
Net Income
-$218.96M
-29.5%
FY2025
Operating Margin
-340.38%
+254.6pp
FY2025
Diluted EPS
-$3.16
-9%
FY2025
Operating Cash Flow
-$249.68M
-51.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| $63.5M | $72.59M | $35.28M | $26.98M | $14.46M | $11.7M | $10.39M | $13.8M | $7.14M | $2.06M | |
| $230.13M | $240.28M | $172.97M | $156.5M | $81.61M | $44.88M | $33.15M | $25.54M | $20.76M | $11.87M | |
| $75.71M | $79.37M | $72.18M | $60.43M | $49.51M | $32.44M | $29.2M | $14.56M | $8.12M | $6.41M | |
| $5.92M | $6.42M | $7.17M | $6.55M | $3.69M | $1.41M | $1.28M | $960K | $712K | $332K | |
| — | — | $2M | — | — | — | — | — | — | — | |
| $305.84M | $319.65M | $245.15M | $216.92M | $131.12M | $77.32M | $62.35M | $40.1M | $28.88M | $18.27M | |
| -$242.34M | -$247.07M | -$209.87M | -$189.95M | -$116.65M | -$65.62M | -$51.96M | -$26.3M | -$21.75M | -$16.21M | |
| — | -340.38% | -594.96% | -704.13% | -806.56% | -560.98% | -500.1% | -190.56% | -304.74% | -787.04% | |
| -$236.43M | -$240.64M | -$202.7M | -$183.4M | -$112.96M | -$64.21M | -$50.68M | -$25.34M | -$21.03M | -$15.88M | |
| $203K | $206K | $1.73M | $3.26M | $3.34M | $2.98M | $457K | — | — | — | |
| $24.72M | $28.26M | $36.08M | $10.74M | $2.41M | -$2.86M | $226K | -$4.56M | -$496K | -$69K | |
| -$217.62M | -$218.81M | -$173.8M | -$179.21M | -$114.24M | -$68.48M | -$51.73M | -$30.86M | -$22.24M | -$16.28M | |
| $1.41M | $152K | -$4.77M | $1.46M | -$1.52M | -$1.66M | -$724K | -$254K | -$396K | -$23K | |
| -$219.03M | -$218.96M | -$169.03M | -$180.66M | -$112.72M | -$66.82M | -$51.01M | -$30.61M | -$21.85M | -$16.26M | |
| — | -301.66% | -479.18% | -669.72% | -779.35% | -571.25% | -490.95% | -221.78% | -306.14% | -789.27% | |
| -$222.85M | -$222.58M | -$167.61M | -$182.36M | -$108.94M | -$67.01M | -$52.67M | -$30.39M | -$23.67M | -$13.9M | |
| USD/shares | — | -$3.16 | -$2.90 | -$5.08 | -$3.80 | -$2.67 | -$2.66 | -$2.77 | — | — |
| USD/shares | — | -$3.16 | -$2.90 | -$5.08 | -$3.80 | -$2.67 | -$2.66 | -$2.77 | — | — |
| shares | — | 69.28M | 58.21M | 35.59M | 29.66M | 25.06M | 19.15M | 11.05M | 438.86K | 333.13K |
| shares | — | 69.28M | 58.21M | 35.59M | 29.66M | 25.06M | 19.15M | 11.05M | 438.86K | 333.13K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.45×
EV/EBIT
—
Peer median 11.37×
P/E (TTM)
—
Peer median 5.37×
Peer medians compare against the 315 similar-size Biotechnology companies (of 522 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Single Reportable Segment | $72,586,000 | $35,275,000 | $26,976,000 | $14,463,000 |